Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) have earned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.

Brokers have set a one year consensus target price of $21.50 for the company and are anticipating that the company will post ($0.22) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Oxford Immunotec Global PLC an industry rank of 113 out of 265 based on the ratings given to related companies.

Several research analysts have commented on OXFD shares. BTIG Research restated a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Thursday, May 4th. Zacks Investment Research lowered shares of Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. ValuEngine upgraded shares of Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Cowen and Company restated a “buy” rating and issued a $22.00 price objective on shares of Oxford Immunotec Global PLC in a report on Thursday. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $26.00 price objective on shares of Oxford Immunotec Global PLC in a report on Thursday.

In other Oxford Immunotec Global PLC news, CEO Peter Wrighton-Smith sold 30,000 shares of the company’s stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $16.06, for a total value of $481,800.00. Following the completion of the transaction, the chief executive officer now directly owns 491,668 shares in the company, valued at approximately $7,896,188.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeff R. Schroeder sold 40,000 shares of the company’s stock in a transaction on Tuesday, May 9th. The stock was sold at an average price of $14.14, for a total transaction of $565,600.00. Following the completion of the transaction, the insider now owns 149,544 shares of the company’s stock, valued at $2,114,552.16. The disclosure for this sale can be found here. Insiders sold a total of 147,085 shares of company stock valued at $2,275,928 over the last 90 days. Company insiders own 7.58% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of OXFD. Endurant Capital Management LP raised its position in shares of Oxford Immunotec Global PLC by 3,456.1% in the first quarter. Endurant Capital Management LP now owns 570,971 shares of the company’s stock valued at $8,844,000 after buying an additional 554,915 shares during the last quarter. AXA raised its position in shares of Oxford Immunotec Global PLC by 52.5% in the first quarter. AXA now owns 917,468 shares of the company’s stock valued at $14,212,000 after buying an additional 315,718 shares during the last quarter. Redmile Group LLC raised its position in shares of Oxford Immunotec Global PLC by 17.9% in the first quarter. Redmile Group LLC now owns 2,004,849 shares of the company’s stock valued at $31,055,000 after buying an additional 303,800 shares during the last quarter. Granahan Investment Management Inc. MA acquired a new position in shares of Oxford Immunotec Global PLC during the first quarter valued at about $4,577,000. Finally, Renaissance Technologies LLC raised its position in shares of Oxford Immunotec Global PLC by 97.8% in the first quarter. Renaissance Technologies LLC now owns 363,300 shares of the company’s stock valued at $5,628,000 after buying an additional 179,600 shares during the last quarter. Institutional investors and hedge funds own 87.47% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/05/zacks-oxford-immunotec-global-plc-nasdaqoxfd-receives-average-recommendation-of-strong-buy-from-analysts.html.

Oxford Immunotec Global PLC (OXFD) traded up 5.66% during midday trading on Wednesday, reaching $18.12. 57,136 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $16.18 and a 200 day moving average price of $14.93. The company’s market cap is $418.14 million. Oxford Immunotec Global PLC has a 12-month low of $8.88 and a 12-month high of $19.51.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). Oxford Immunotec Global PLC had a negative net margin of 34.58% and a negative return on equity of 35.76%. The business had revenue of $26.10 million during the quarter, compared to analyst estimates of $25.05 million. During the same period in the prior year, the business earned ($0.29) EPS. The company’s revenue for the quarter was up 35.9% on a year-over-year basis. On average, analysts expect that Oxford Immunotec Global PLC will post ($1.07) EPS for the current fiscal year.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.